EXHIBIT 5.1
![LOGO](https://capedge.com/proxy/8-K/0001193125-18-283933/g625829g0926144704072.jpg)
September 25, 2018
AnaptysBio, Inc.
10421 Pacific Center Court, Suite 200
San Diego, California 92121
Gentlemen/Ladies:
We deliver this opinion with respect to certain matters in connection with the offering by AnaptysBio, Inc., a Delaware corporation (the “Company”), of up to 2,530,000 shares of the Company’s common stock, par value $0.001 per share (the “Shares”), to be issued pursuant to that certain Underwriting Agreement (the “Underwriting Agreement”), dated as of even date herewith, between the Company, Credit Suisse Securities (USA) LLC, J.P. Morgan Securities LLC and Jefferies LLC, as representatives (the “Representatives”) of the underwriters named in Schedule I thereto. The Shares were registered pursuant to the Registration Statement on FormS-3 (FileNo. 333-222868) filed by the Company with the Securities and Exchange Commission (the “Commission”) on February 5, 2018 under the Securities Act of 1933, as amended (the “Securities Act”), declared effective on February 5, 2018 (the “Registration Statement”), the prospectus dated February 5, 2018 included in the Registration Statement (the “Base Prospectus”), and as supplemented by the preliminary prospectus supplement dated September 24, 2018 and the final prospectus supplement dated September 25, 2018, both of which were filed with the Commission pursuant to Rule 424(b) under the Securities Act (the “Prospectus Supplement” and, together with the Base Prospectus, the “Prospectus”). The offering of the Shares by the Company pursuant to the Registration Statement, the Prospectus and the Underwriting Agreement is referred to herein as the “Offering.”
In connection with our opinion expressed below we have examined originals or copies of the Underwriting Agreement, the Company’s Restated Certificate of Incorporation filed with, and certified by, the Delaware Secretary of State (the “Restated Certificate”) and Amended and Restated Bylaws (the “Restated Bylaws”), certain corporate proceedings of the Company’s board of directors (the “Board”) and or a committee or committees of the Board and the Company’s stockholders relating to the Registration Statement, the Company’s Restated Certificate and Restated Bylaws, and such other agreements, documents, certificates and statements of the Company, its transfer agent and public or government officials, as we have deemed advisable, and have examined such questions of law as we have considered necessary. We have assumed the authenticity of all documents submitted to us as originals, the genuineness of all signatures on documents submitted to us, the conformity to originals of all documents submitted to us as copies, and the absence of any undisclosed termination, waiver or amendment to any document reviewed by us. In giving our opinion, we have also relied upon a good standing certificate regarding the Company issued by the Delaware Secretary of State and a management certificate addressed to us and dated of even date herewith executed by the Company containing certain factual representations by the Company (the “Management Certificate”).